Patents Examined by Rebecca Cook
  • Patent number: 6720337
    Abstract: The invention refers to pharmaceutical compositions which have an enhanced antitumor activity or reduced side effect(s) comprising a known active substance having antitumor effect or a pharmaceutically acceptable salt thereof and a hydroximic acid derivative of formula (I) or a therapeutically useful acid addition salt thereof.
    Type: Grant
    Filed: March 27, 2002
    Date of Patent: April 13, 2004
    Assignee: N-Gene Research Laboratories, Inc.
    Inventor: Balazs Sumegi
  • Patent number: 6716867
    Abstract: The present invention relates to a method of sedating a patient while in the intensive care unit comprising administering dexmedetomidine of a pharmaceutically acceptable salt thereof to the patient, wherein the patient remains arousable and orientated.
    Type: Grant
    Filed: December 6, 2000
    Date of Patent: April 6, 2004
    Assignee: Orion Corporation
    Inventors: Riku Aantaa, Romeo Bachand, Esa Heinonen
  • Patent number: 6716879
    Abstract: Disclosed and claimed is a method for treating tumors using sulfonylamino-substituted N-aryl- or heteroarylcarboxamide derivatives.
    Type: Grant
    Filed: August 29, 2001
    Date of Patent: April 6, 2004
    Assignee: Compass Pharmaceuticals, LLC
    Inventor: Irwin Braude
  • Patent number: 6713510
    Abstract: The present invention provides compositions useful for the treatment of inflammation in humans, and related methods of treatment for the same. In one embodiment the composition is In another embodiment, the composition is Additional alternative embodiments are R or R″ that are therapeutic moieties.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: March 30, 2004
    Assignee: Nobex Corporation
    Inventors: Nnochiri Nkem Ekwuribe, Jennifer A. Riggs
  • Patent number: 6710050
    Abstract: The present invention provides a new stable pharmaceutical composition containing 5-[[4-[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione as active ingredient.
    Type: Grant
    Filed: May 23, 2001
    Date of Patent: March 23, 2004
    Assignees: Novo Nordisk A/S, Dr. Reddy's Research Foundation
    Inventors: Helle Weibel, Thyge Borup Hjorth
  • Patent number: 6706759
    Abstract: Dithiocarbamate, particularly tetraethylthiuram disulfide, and thiocarbamate anions strongly inhibit the growth of cancer cells of a variety of cell types. Such inhibitory effect is enhanced by heavy metal ions such as copper ions, cytokines and ceruloplasmin. A method is presented for using tetraethylthiuram disulfide to reduce tumor growth, and to potentiate the effect of other anticancer agents.
    Type: Grant
    Filed: October 5, 2000
    Date of Patent: March 16, 2004
    Assignee: Charlotte-Mecklenburg Hospital Authority
    Inventor: Thomas Preston Kennedy
  • Patent number: 6699906
    Abstract: A method of reducing exertion related muscle discomfort in a mammal is provided, in which a supplement containing a lactic acid salt is administered a specified period of time before exercising. A method of marketing a lactic acid salt supplement is also provided.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: March 2, 2004
    Inventor: Carl Holmes
  • Patent number: 6693100
    Abstract: The use for the manufacture of a medicament for treating psoriasis of dexrazoxane, the d-isomer of 1,2-bis(3,5-dioxopiperazin-1-yl)-propane, or a physiologically acceptable salt thereof.
    Type: Grant
    Filed: June 11, 2002
    Date of Patent: February 17, 2004
    Inventors: Iervant Zarmanian, Jadranka Rogan-Grgas
  • Patent number: 6689809
    Abstract: This invention relates to methods for prevention of cancers, certain non-cancer, hormone dependent diseases and/or cardiovascular diseases in a person, based on administering of hydroxymatairesinol to said person. The invention also concerns a method for increasing the level of enterolactone or another metabolite of hydroxymatairesinol in a person's serum thereby causing prevention of a cancer or a certain non-cancer, hormone dependent disease in a person, based on administering of hydroxymatairesinol to said person. Furthermore, this invention relates to pharmaceutical preparations, food additives and food products comprising hydroxymatairesinol.
    Type: Grant
    Filed: October 10, 2001
    Date of Patent: February 10, 2004
    Assignee: Hormos Nutraceutical Oy Ltd.
    Inventors: Markku Ahotupa, Christer Eckerman, Lauri Kangas, Sari Mäkelä, Niina Saarinen, Risto Santti, Anni Wärri
  • Patent number: 6677325
    Abstract: A method for controlling estrone or estrodiol production comprising administering a ring system compound comprising a sulphamic acid ester group; wherein said compound is an inhibitor of an enzyme having steroid sulphatase activity (EC 3.1.6.2); and wherein if the sulphamic acid ester group of said compound is replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (EC 3.1.6.2) at a pH 7.4 and 37° C. it provides a Km value of less than 50 &mgr;M. A method to target the estrogen metabolic pathway comprising administering a ring system compound comprising a sulphamic acid ester group; wherein said compound is an inhibitor of an enzyme having steroid sulphatase activity (EC 3.1.6.2); and wherein if the sulphamic acid ester group of said compound is replaced with a sulphate group to form a sulphate compound and incubated with a steroid sulphatase enzyme (EC 3.1.6.2) at a pH 7.4 and 37° C. it provides a Km value of less than 50 &mgr;M.
    Type: Grant
    Filed: February 21, 2002
    Date of Patent: January 13, 2004
    Assignee: Sterix Ltd.
    Inventors: Michael John Reed, Barry Victor Lloyd Potter
  • Patent number: 6656945
    Abstract: 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-one compounds which are selective inhibitors of cGMP PDE are useful in the treatment of erectile dysfunction (impotence) in male animals, including man.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: December 2, 2003
    Assignee: Pfizer Inc
    Inventors: Simon Fraser Campbell, Alexander Roderick MacKenzie, Anthony Wood
  • Patent number: 6656931
    Abstract: This invention provides methods of increasing urine flow in humans while minimizing the loss of electrolytes or ions, the methods comprising administering to a human in need thereof a combination of N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)ylcarbonyl)-3-chlorophenyl]-5-fluoro-2-methylbenzamide (or a pharmaceutically acceptable salt thereof), also known as VPA-985, and one or more diuretic agents, as well as pharmaceutical compositions and kits or packages for such combinations.
    Type: Grant
    Filed: June 4, 2002
    Date of Patent: December 2, 2003
    Assignee: Wyeth Holdings Corporation
    Inventors: Evelyn Ellis-Grosse, Gayle P. Orczyk
  • Patent number: 6653348
    Abstract: The present invention provides compositions useful for the treatment of inflammation in humans, and related methods of treatment for the same. In one embodiment the composition is In another embodiment, the composition is Additional alternative embodiments are R or R″ that are therapeutic moieties.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: November 25, 2003
    Assignee: Nobex Corporation
    Inventors: Nnochiri Nkem Ekwuribe, Jennifer A. Riggs
  • Patent number: 6646004
    Abstract: The present invention provides the use of (−)(3-trihalomethylphenoxy)(4-halophenyl)acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes and hyperlipidemia.
    Type: Grant
    Filed: October 31, 2000
    Date of Patent: November 11, 2003
    Assignees: Metabolex, Inc., DiaTex, Inc.
    Inventors: Kenneth L. Luskey, Jian Luo
  • Patent number: 6642258
    Abstract: The invention relates to the use of a central cannabinoid receptor antagonist for the preparation of medicinal products that are useful in treating and preventing neuroinflammatory pathologies.
    Type: Grant
    Filed: March 21, 2002
    Date of Patent: November 4, 2003
    Assignee: Sanofi-Synthelabo
    Inventors: Bernard Bourrie, Pierre Casellas
  • Patent number: 6638966
    Abstract: Melatonin (N-acetyl-5-methoxytryptamine), or its biologically active analogues, are used to induce anesthesia.
    Type: Grant
    Filed: February 19, 2002
    Date of Patent: October 28, 2003
    Assignee: University of Iowa Research Foundation
    Inventors: Max T. Baker, Mohamed Naguib Attala
  • Patent number: 6635675
    Abstract: The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject comprising administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and a greater inhibition of norepinephrine reuptake than serotonin reuptake, and wherein said compound is not administered adjunctively with phenylalanine or tyrosine. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
    Type: Grant
    Filed: November 5, 2001
    Date of Patent: October 21, 2003
    Assignee: Cypress Bioscience, Inc.
    Inventors: Jay D. Kranzler, Srinivas G. Rao
  • Patent number: 6630511
    Abstract: Water-soluble salts of 2-difluoromethyl-2,5-diaminopentanoic acid (DFMO) with polycations, their synthesis and uses are described.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: October 7, 2003
    Inventor: Rolland F. Hebert
  • Patent number: 6627659
    Abstract: The present invention relates to methods of decreasing the effects of oxidative stress in patients undergoing hemodialysis by intravenously administering N-acetylcysteine or a pharmaceutically acceptable salt thereof to the patient.
    Type: Grant
    Filed: October 22, 2001
    Date of Patent: September 30, 2003
    Assignee: Zambon Group S.p.A.
    Inventor: Francesco Santangelo
  • Patent number: 6624194
    Abstract: The present invention provides the use of (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives and compositions in the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia. It further provides (−) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives that are useful for the treatment of insulin resistance, Type 2 diabetes, hyperlipidemia and hyperuricemia.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: September 23, 2003
    Assignees: Metabolex, Inc., DiaTex, Inc.
    Inventors: Kenneth L. Luskey, Jian Luo, Zuchun Zhao